Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trends in the Cath Lab: FFR Emerging as Stenting Gatekeeper

Executive Summary

Clinical advancements in the cardiac catheterization lab most often occur in fits and starts, rarely in smooth progressions. Momentous developments like the percutaneous transluminal coronary angioplasty catheter, the bare metal stent, and then the drug-eluting stent shook both the profession and the industry. More recently, measurement of fractional flow reserve, a unique tool that assesses the severity of a coronary artery blockage by comparing blood flow at the distal and proximal ends of the lesion, is being utilized in greater numbers by interventional cardiologists as a combined refinement and development that shows great promise for both improving patient outcomes and lowering cost, all with few known negative consequences. FFR is a unique tool that assesses the severity of a coronary artery blockage by comparing blood flow at the distal and proximal ends of the lesion.

You may also be interested in...



Senate Finance Committee Examines Improper Cardiac Stent Implants

The Senate Finance Committee signaled enhanced scrutiny into unnecessary use of stents and other implantable devices in a report released Dec. 6.

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered. 

OIG: FDA’s EUA Approach Allowed Bad Tests To Reach Market

A review by a government watchdog found the FDA’s review process for COVID-19 diagnostics was plagued by issues including allowing low-quality tests to slip through, high reviewer workloads, and manufacturer frustration.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT035426

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel